On August 24, 2020 IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX-V: IGX) (OTCQB:IGXT) reported that the Company’s board of directors amended the expiration time of Stock Options granted to Andre Godin, President and CFO, under the 2006 Stock Option Plan on July 20, 2015 (Press release, IntelGenx, AUG 24, 2020, View Source [SID1234563974]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The extension was granted following the end of an insider trading black-out period during which the stock options automatically extended in accordance with the insider trading black-out provision of the Company’s Second Amended 2016 Stock Option Plan.

The new expiration date is July 19, 2025, the original exercise price of CAD$0.75 (US$0.58) and all other terms remain unchanged.

The amendment is subject to final TSX-Venture Exchange approval.